PRA Health Sciences (NASDAQ: PRAH) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.
Institutional & Insider Ownership
48.9% of Intellia Therapeutics shares are owned by institutional investors. 2.1% of PRA Health Sciences shares are owned by company insiders. Comparatively, 12.8% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for PRA Health Sciences and Intellia Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|PRA Health Sciences||0||1||9||0||2.90|
PRA Health Sciences presently has a consensus target price of $88.60, suggesting a potential upside of 9.79%. Intellia Therapeutics has a consensus target price of $30.17, suggesting a potential upside of 49.04%. Given Intellia Therapeutics’ higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than PRA Health Sciences.
This table compares PRA Health Sciences and Intellia Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|PRA Health Sciences||5.64%||21.66%||7.02%|
Earnings & Valuation
This table compares PRA Health Sciences and Intellia Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|PRA Health Sciences||$1.81 billion||2.82||$68.17 million||$1.79||45.08|
|Intellia Therapeutics||$16.48 million||44.32||-$31.63 million||($1.56)||-12.97|
PRA Health Sciences has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than PRA Health Sciences, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
PRA Health Sciences has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.93, meaning that its stock price is 193% more volatile than the S&P 500.
PRA Health Sciences beats Intellia Therapeutics on 8 of the 13 factors compared between the two stocks.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc. is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The Company’s service offerings include product registration, strategic solutions and early development services.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company’s division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company’s subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.